Next Article in Journal
Bridging Discoveries and Treatments: The New Landscape of Breast Cancer Research
Next Article in Special Issue
Towards Improved XAI-Based Epidemiological Research into the Next Potential Pandemic
Previous Article in Journal
Optimizing Soil Health and Sorghum Productivity through Crop Rotation with Quinoa
Previous Article in Special Issue
Persistent Olfactory and Taste Dysfunction after COVID-19
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 14
Issue 6
10.3390/life14060746
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Malnutrition and the Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Multi-Institutional Population-Based Propensity Score-Matched Analysis

by
Cheng-Ya Lee
1,
Yung-Chun Liang
2,
Wan-Hsuan Hsu
2,
Ya-Wen Tsai
3,
Ting-Hui Liu
4,
Po-Yu Huang
2,
Min-Hsiang Chuang
5,
Kuo-Chuan Hung
6,7,
Mei-Chuan Lee
8,9,
Tsung Yu
8,
Chih-Cheng Lai
7,10,
Tzu-Chieh Weng
11,* and
Jheng-Yan Wu
8,12,*
1
Division of Cardiovascular Surgery, Department of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan
2
Department of Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan
3
Division of Preventive Medicine, Chi Mei Medical Center, Tainan 710, Taiwan
4
Department of Psychiatry, Chi Mei Medical Center, Tainan 710, Taiwan
5
Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan
6
Department of Anesthesiology, Chi Mei Medical Center, Tainan 710, Taiwan
7
School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung City 804, Taiwan
8
Department of Public Health, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
9
Department of Pharmacy, Chi Mei Medical Center, Tainan 710, Taiwan
10
Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan 710, Taiwan
11
Division of Hospital Medicine, Department of Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan
12
Department of Nutrition, Chi Mei Medical Center, Tainan 710, Taiwan
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Authors to whom correspondence should be addressed.
Life 2024, 14(6), 746; https://doi.org/10.3390/life14060746
Submission received: 19 May 2024 / Revised: 8 June 2024 / Accepted: 10 June 2024 / Published: 12 June 2024
(This article belongs to the Special Issue COVID-19 and SARS-CoV-2 Investigations: Characteristics, Clinical Course, Prevention, Treatment and Prognosis)
Browse Figures
Versions Notes

Abstract

:
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global health crisis, exacerbating issues like malnutrition due to increased metabolic demands and reduced intake during illness. Malnutrition, a significant risk factor, is linked to worse outcomes in patients with COVID-19, such as increased mortality and extended hospital stays. This retrospective cohort study investigated the relationship between malnutrition and clinical outcomes within 90–180 days using data obtained from the TriNetX database. Patients aged >18 years diagnosed with COVID-19 between 1 January 2022, and 31 March 2024 were enrolled in the study. The propensity score-matching (PSM) method was used to match patients with malnutrition (malnutrition group) and those without malnutrition (control group). The primary composite outcome was the cumulative hazard ratio (HR) for post-COVID-19 condition, all-cause hospitalization, and all-cause mortality between 90 days and 180 days after COVID-19 diagnosis. The secondary outcomes were the individual components of the primary outcomes. Two cohorts, each consisting of 15,004 patients with balanced baseline characteristics, were identified using PSM. During the 90–180-day follow-up period, the malnutrition group exhibited a higher incidence of all-cause hospitalization, mortality, or post-COVID-19 condition (HR = 2.315, 95% confidence interval: 2.170–2.471, p < 0.0001). Compared with patients with COVID-19 without malnutrition, those with malnutrition may be associated with a higher risk of adverse clinical outcomes.

1. Introduction

Coronavirus disease (COVID-19), an acute respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered a global pandemic and public health outbreak [1]. As of 5 May 2024, over 700 million cases and 7 million deaths have been reported worldwide [2]. The spectrum of symptoms in infected individuals varies widely; some patients remain asymptomatic, while others develop mild symptoms such as cough, chills, fever, fatigue, and dyspnea [3,4]. More severe manifestations include sepsis, acute respiratory distress syndrome, heart failure, septic shock, and multi-organ dysfunction due to the acute inflammatory response [5,6]. Beyond these immediate effects, approximately 10% of individuals experience long-term consequences known as the post-acute sequelae of SARS-CoV-2 infection (PASC) or “long COVID.” PASC can involve a range of persistent symptoms, including chronic fatigue, respiratory difficulties, cognitive impairment, and cardiovascular issues, extending for months beyond the initial recovery period [7,8,9].
Building on an understanding of the impact of COVID-19, the factors that can exacerbate the severity of the disease must be investigated. Malnutrition, which can manifest in acute, subacute, or chronic form, is one such factor. It is characterized by progressive weight loss, insufficient energy intake, muscle and fat loss, fluid accumulation, and reduced grip strength [10,11]. It is a significant independent risk factor for increased morbidity and mortality across various diseases, as it leads to heightened susceptibility to infections or superinfections [12].
Malnutrition may influence the severity of COVID-19 through several mechanisms, including impairment of the immune response, increased inflammation, and delayed recovery. Deficiencies in key nutrients, such as vitamins A, C, and D, zinc, and protein–energy malnutrition can reduce lymphocyte proliferation, impair immune function and antibody production, and weaken the mucosal barriers that are crucial for preventing pathogen entry. These deficiencies can compromise pulmonary function, which can weaken the respiratory muscles and reduce the pulmonary immune defenses, thereby facilitating more severe respiratory symptoms and extensive viral damage [10,11,12].
Previous meta-analyses have indicated that nearly 49% of patients with COVID-19 experience malnutrition [13]. Observational studies have suggested that malnutrition in these patients correlates with poorer outcomes, including increased rates of mechanical ventilation, mortality, and prolonged hospital stay [14,15,16,17,18,19].
However, much of the existing evidence is derived from retrospective studies conducted at a single center. Therefore, more comprehensive studies with larger sample sizes are needed. This study aimed to explore the association between malnutrition and clinical outcomes in patients with SARS-CoV-2 infection over a period of 90–180 days using an international database.

2. Materials and Methods

2.1. Data Source

The data used in this study were collected from the TriNetX Research Network. The TriNetX database shares electronic medical record data (diagnoses, procedures, medications, laboratory values, genomic information, and types of visits) of approximately 140 million individuals at 119 healthcare organizations (HCOs) [20]. Numerous observational studies have utilized the TriNetX database, particularly when conducting COVID-19 research [21,22,23,24]. The TriNetX platform provides integrated tools for analyzing patient-level data and presents outcomes to researchers as consolidated reports. Considering that the data utilized from TriNetX were anonymized, written informed consent was not required. This study was approved by the Institutional Review Board of the Chi Mei Medical Center (approval no. 11302-E01).

2.2. Patient Selection and Exposure

Patients aged >18 years who had more than two visits to HCOs from 1 January 2022 to 31 March 2024 and were diagnosed with COVID-19 (confirmed by a positive polymerase chain reaction test [laboratory test code with TNX: LAB:9088] or an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code U07.1) [25,26,27] were included in the study. To ensure consistency in terms of disease severity, patients who died within 90 days or were hospitalized within 7 days after contracting COVID-19 were excluded. Patients were further divided into the malnutrition and control groups based on whether they exhibited signs of malnutrition (ICD-10 cm codes: E40–E46) within 90 days before the index date. Our initial cohort from 1 January 2022 to 31 March 2024, consisted of 3,038,057 patients with COVID-19, including 23,364 with malnutrition and 3,014,693 without malnutrition (Figure 1).

2.3. Covariates

To balance the distribution between groups at baseline, we selected covariates for matching based on CDC [28]. The baseline variables used to match the two study groups included (a) demographics such as age, sex, and race; (b) potential health risks linked to socioeconomic factors, including housing and financial conditions, educational attainment and literacy levels, employment status, and occupational exposure to hazards; and (c) comorbid conditions such as alcohol-related disorders, nicotine dependence, hypertension, hyperlipidemia, diabetes mellitus, neoplasms, chronic diseases of the lower respiratory tract, liver diseases, chronic kidney disease, end-stage renal disease, cerebrovascular disease, heart failure, and atrial fibrillation.

2.4. Outcomes

The primary outcome of this study was a composite of all-cause hospitalization, all-cause mortality, or post-COVID-19 condition. The secondary outcomes were the individual components of the primary outcome, including all-cause hospitalization, all-cause mortality, and post-COVID-19 condition. The follow-up period was 90–180 days after the index date.

2.5. Statistical Analysis

Statistical analyses were performed using the integrated functions of the TriNetX platform. The baseline characteristics of the malnutrition and control groups were expressed as the means, standard deviations, counts, and percentages. To correct imbalances in baseline covariates, a 1:1 PSM was employed. The PSM technique utilized a nearest-neighbor matching algorithm with a caliper width set at 0.1 of pooled standard deviations. Variables with a standardized difference of less than 0.1 between groups were considered adequately matched. Following PSM, the cumulative incidence of each outcome was estimated using Cox regression models and the results were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). Additionally, Kaplan–Meier curves were generated to assess the survival distributions between the groups, with significance evaluated using the log-rank test. A p value of <0.05 was considered significant.

2.6. Subgroup Analysis

Subgroup analyses were performed using a stratified approach to explore variations in outcomes based on sex, age, race, vaccination status, and the antiviral agent used.

3. Results

3.1. Demographic Characteristics

The baseline characteristics of the two groups are presented in Table 1. Prior to PSM, notable differences were noted in the demographic and health profiles of the two groups. Specifically, individuals in the malnutrition group were generally older than those in the control group (mean age: 66.0 ± 17.5 vs. 50.6 ± 19.2). The malnutrition group also had a higher proportion of women (58.7% vs. 46.4%). In terms of comorbidities, the malnutrition group exhibited a higher prevalence of alcohol-related disorders (8.9% vs. 2.6%), nicotine dependence (17.7% vs. 7.9%), hypertension (52.4% vs. 30%), hyperlipidemia (41.4% vs. 28.4%), diabetes mellitus (29.4% vs. 14.4%), neoplasms (34.3% vs. 20.5%), chronic lower respiratory diseases (25.5% vs. 15.3%), liver diseases (15.9% vs. 6.3%), chronic kidney disease (22.4% vs. 6.6%), end-stage renal disease (4.8% vs. 1.1%), cerebrovascular diseases (20.1% vs. 4.9%), atrial fibrillation and flutter (16.5% vs. 4.9%), and ischemic heart diseases (27.3% vs. 9.5%). Following PSM, both groups comprised 15,004 patients, each with well-balanced demographic characteristics, as summarized in Table 1.

3.2. Primary Outcomes

During the 90–180-day follow-up period, the all-cause hospitalization, mortality, or long COVID-19 rate was higher in the malnutrition group (17.9%) than in the control group (9.2%), with an HR of 2.315 (95% CI: 2.170–2.471, p < 0.001; Figure 2, Table 2).

3.3. Secondary Outcomes

For the individual component outcomes during the 90–180-day follow-up period, the malnutrition group showed a higher risk of all-cause hospitalization (HR = 2.151, 95% CI: 2.008–2.304), all-cause mortality (HR = 4.459, 95% CI: 3.699–5.376), and post-COVID-19 condition (HR = 2.707, 95% CI: 1.913–3.832) than the control group (Table 2).

3.4. Subgroup Analysis

The risk of the primary outcome was examined based on age, sex, race, vaccination status, and the antiviral agent used (Table 3). Subgroup analyses showed consistent results for each subgroup. In terms of the other secondary outcomes, similar trends were observed in the subgroup analyses (Table 4).

4. Discussion

This study used a large sample size to investigate the association between malnutrition and clinical outcomes in patients with COVID-19 over a 90–180-day follow-up period. Our findings highlight that patients with COVID-19 experiencing malnutrition have a significantly higher risk of severe outcomes, including all-cause hospitalization, all-cause mortality, and post-COVID-19 condition. Notably, the effect size of all-cause mortality in the malnutrition group was fourfold higher than that in the control group, indicating a substantial impact of nutritional status on COVID-19 severity.
The underlying mechanisms by which malnutrition exacerbates COVID-19 severity involve both direct and indirect effects on patient health. Malnutrition weakens immune defense mechanisms, as evidenced by a reduced lymphocyte count and impaired phagocytic function, which are critical for combating viral infections [29,30]. Deficiencies in essential proteins, vitamins, and minerals further weaken physical barriers and cellular immunity. This predisposition not only increases susceptibility to severe infections but also increases the risk of prolonged illness and complications [31,32,33,34].
Furthermore, malnutrition exacerbates the inflammatory cascade associated with COVID-19. It induces an imbalanced cytokine profile, promoting inflammatory pathways that can lead to the occurrence of cytokine storm syndrome, a known predictor of severe outcomes in COVID-19. Uncontrolled inflammation can result in tissue damage, multi-organ failure, and heightened mortality risk [32,35,36,37,38,39].
Consistent with previous studies, malnutrition amplifies the severity of infectious diseases, including COVID-19 [3,12,40,41,42,43,44]. A meta-analysis of 12 studies demonstrated a similar trend, showing that malnourished patients had significantly higher odds of in-hospital mortality (odds ratio = 3.43, 95% CI: 2.55–4.60) during a 90-day follow-up [45]. Our study builds on these findings by including non-hospitalized patients and extending the follow-up duration, thus providing a more comprehensive view of the impact of malnutrition on COVID-19 outcomes in various settings. Additionally, our study addressed some of the limitations observed in previous studies, such as small sample sizes and short follow-up periods, by utilizing a larger and more diverse cohort with a longer observation period. This approach enhances the generalizability and applicability of our findings, suggesting robust associations across various healthcare settings and populations.
The strong association between malnutrition and adverse COVID-19 outcomes underscores the necessity of early nutritional screening and intervention in patients with COVID-19. The implementation of nutritional support strategies can potentially reduce disease severity and improve clinical outcomes. Physicians and dietitians should consider integrated care pathways that incorporate nutritional assessments and tailored interventions as part of standard care for patients with COVID-19.
Although our findings are significant, they highlight the need for further research to explore the causal relationships and effectiveness of specific nutritional interventions in improving COVID-19 prognosis. Prospective and randomized controlled trials are essential to determine the specific nutrients and dietary interventions that are most effective in mitigating the impact of malnutrition on COVID-19 severity.
This study has several strengths. First, although the existing research often relies on data from a single hospital with limited sample sizes and generalizability, our study draws from a vast and diverse population. This diversity enhances the relevance and generalizability of our findings to broader real-world settings. Second, we employed PSM to ensure comparability between the groups, effectively controlling for potential confounding factors related to the variables of interest and observed outcomes. Finally, the consistency observed across various subgroup analyses adds further credibility to our findings.
This study has some limitations. First, potential information bias and coding errors in the electronic health records database may have occurred; however, these errors were likely consistent between the groups, which minimizes their impact on our findings [46]. Second, relying on ICD-10 cm codes to determine the history of malnutrition may underestimate its true prevalence. Third, although our data suggest significant associations, they do not establish causality. Fourth, due to database limitations, we could not determine the countries from which these patients originated. Finally, to control for disease severity and reduce heterogeneity, we excluded patients who were initially hospitalized and deceased within 90 days from the index date, limiting the generalizability of our findings.

5. Conclusions

This study demonstrated that malnutrition is associated with a significantly higher risk of all-cause hospitalization, mortality, or post-COVID-19 condition compared with the control group. Therefore, malnutrition is a potential risk factor for poor clinical outcomes in patients with COVID-19. These findings highlight the critical role of malnutrition in exacerbating the severity of COVID-19. The robustness of the data, enhanced by the large sample size and diverse patient population, provides compelling evidence supporting the integration of nutritional evaluations and interventions in the management of COVID-19.

Author Contributions

Conceptualization, C.-Y.L., T.-C.W. and J.-Y.W.; methodology, T.-H.L.; software, M.-H.C.; validation, W.-H.H. and Y.-W.T.; writing—original draft preparation, Y.-C.L.; writing—review and editing, K.-C.H., M.-C.L., T.Y., C.-C.L., T.-C.W. and J.-Y.W.; visualization, W.-H.H. and P.-Y.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was approved by the Institutional Review Board of the Chi Mei Medical Center (approval no. 11302-E01).

Informed Consent Statement

Informed consent was not obtained, since all data were taken anonymously from the database of the hospital.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. World Health Organization. Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 9 May 2024).
  2. World Health Organization. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed on 19 May 2024).
  3. Barazzoni, R.; Bischoff, S.C.; Busetto, L.; Cederholm, T.; Chourdakis, M.; Cuerda, C.; Delzenne, N.; Genton, L.; Schneider, S.; Singer, P.; et al. Nutritional management of individuals with obesity and COVID-19: ESPEN expert statements and practical guidance. Clin. Nutr. 2022, 41, 2869–2886. [Google Scholar] [CrossRef] [PubMed]
  4. Lai, C.C.; Hsueh, P.R. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment. J. Med. Virol. 2023, 95, e28430. [Google Scholar] [CrossRef] [PubMed]
  5. Barazzoni, R.; Bischoff, S.C.; Breda, J.; Wickramasinghe, K.; Krznaric, Z.; Nitzan, D.; Pirlich, M.; Singer, P. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin. Nutr. 2020, 39, 1631–1638. [Google Scholar] [CrossRef] [PubMed]
  6. Lai, C.C.; Ko, W.C.; Lee, P.I.; Jean, S.S.; Hsueh, P.R. Extra-respiratory manifestations of COVID-19. Int. J. Antimicrob. Agents 2020, 56, 106024. [Google Scholar] [CrossRef] [PubMed]
  7. Davis, H.E.; McCorkell, L.; Vogel, J.M.; Topol, E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023, 21, 133–146. [Google Scholar] [CrossRef] [PubMed]
  8. Lai, C.C.; Hsu, C.K.; Yen, M.Y.; Lee, P.I.; Ko, W.C.; Hsueh, P.R. Long COVID: An inevitable sequela of SARS-CoV-2 infection. J. Microbiol. Immunol. Infect. 2023, 56, 1–9. [Google Scholar] [CrossRef] [PubMed]
  9. Nalbandian, A.; Sehgal, K.; Gupta, A.; Madhavan, M.V.; McGroder, C.; Stevens, J.S.; Cook, J.R.; Nordvig, A.S.; Shalev, D.; Sehrawat, T.S.; et al. Post-acute COVID-19 syndrome. Nat. Med. 2021, 27, 601–615. [Google Scholar] [CrossRef] [PubMed]
  10. White, J.V.; Guenter, P.; Jensen, G.; Malone, A.; Schofield, M. Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: Characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). JPEN J. Parenter. Enteral Nutr. 2012, 36, 275–283. [Google Scholar] [CrossRef]
  11. Jensen, G.L.; Mirtallo, J.; Compher, C.; Dhaliwal, R.; Forbes, A.; Grijalba, R.F.; Hardy, G.; Kondrup, J.; Labadarios, D.; Nyulasi, I.; et al. Adult starvation and disease-related malnutrition: A proposal for etiology-based diagnosis in the clinical practice setting from the International Consensus Guideline Committee. JPEN J. Parenter. Enteral Nutr. 2010, 34, 156–159. [Google Scholar] [CrossRef]
  12. Schneider, S.M.; Veyres, P.; Pivot, X.; Soummer, A.M.; Jambou, P.; Filippi, J.; van Obberghen, E.; Hébuterne, X. Malnutrition is an independent factor associated with nosocomial infections. Br. J. Nutr. 2004, 92, 105–111. [Google Scholar] [CrossRef]
  13. Abate, S.M.; Chekole, Y.A.; Estifanos, M.B.; Abate, K.H.; Kabthymer, R.H. Prevalence and outcomes of malnutrition among hospitalized COVID-19 patients: A systematic review and meta-analysis. Clin. Nutr. ESPEN 2021, 43, 174–183. [Google Scholar] [CrossRef] [PubMed]
  14. Kurtz, A.; Grant, K.; Marano, R.; Arrieta, A.; Grant, K., Jr.; Feaster, W.; Steele, C.; Ehwerhemuepha, L. Long-term effects of malnutrition on severity of COVID-19. Sci. Rep. 2021, 11, 14974. [Google Scholar] [CrossRef] [PubMed]
  15. Allard, L.; Ouedraogo, E.; Molleville, J.; Bihan, H.; Giroux-Leprieur, B.; Sutton, A.; Baudry, C.; Josse, C.; Didier, M.; Deutsch, D.; et al. Malnutrition: Percentage and Association with Prognosis in Patients Hospitalized for Coronavirus Disease 2019. Nutrients 2020, 12, 3679. [Google Scholar] [CrossRef] [PubMed]
  16. Hu, X.; Deng, H.; Wang, Y.; Chen, L.; Gu, X.; Wang, X. Predictive value of the prognostic nutritional index for the severity of coronavirus disease 2019. Nutrition 2021, 84, 111123. [Google Scholar] [CrossRef] [PubMed]
  17. Li, G.; Zhou, C.L.; Ba, Y.M.; Wang, Y.M.; Song, B.; Cheng, X.B.; Dong, Q.F.; Wang, L.L.; You, S.S. Nutritional risk and therapy for severe and critical COVID-19 patients: A multicenter retrospective observational study. Clin. Nutr. 2021, 40, 2154–2161. [Google Scholar] [CrossRef] [PubMed]
  18. Li, T.; Zhang, Y.; Gong, C.; Wang, J.; Liu, B.; Shi, L.; Duan, J. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. Eur. J. Clin. Nutr. 2020, 74, 871–875. [Google Scholar] [CrossRef] [PubMed]
  19. Zhang, P.; He, Z.; Yu, G.; Peng, D.; Feng, Y.; Ling, J.; Wang, Y.; Li, S.; Bian, Y. The modified NUTRIC score can be used for nutritional risk assessment as well as prognosis prediction in critically ill COVID-19 patients. Clin. Nutr. 2021, 40, 534–541. [Google Scholar] [CrossRef] [PubMed]
  20. TriNetX. TriNetX Research Network. Available online: https://trinetx.com/ (accessed on 9 May 2024).
  21. Huang, S.W.; Yeh, W.B.; Chen, H.Y.; Yong, S.B. Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2,442,686 patients. J. Med. Virol. 2023, 95, e29101. [Google Scholar] [CrossRef]
  22. Chuang, M.H.; Wu, J.Y.; Liu, T.H.; Hsu, W.H.; Tsai, Y.W.; Huang, P.Y.; Lai, C.C. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection. J. Med. Virol. 2023, 95, e28750. [Google Scholar] [CrossRef] [PubMed]
  23. Hsu, W.H.; Tsai, Y.W.; Wu, J.Y.; Liu, T.H.; Lai, C.C. Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors. J. Infect. 2023, 86, e107–e110. [Google Scholar] [CrossRef]
  24. Wu, J.Y.; Liu, M.Y.; Liu, T.H.; Chuang, M.H.; Hsu, W.H.; Huang, P.Y.; Tsai, Y.W.; Kuo, C.Y.; Yeh, C.T.; Lai, C.C. Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19. J. Med. Virol. 2023, 95, e28866. [Google Scholar] [CrossRef] [PubMed]
  25. Tsai, Y.W.; Wu, J.Y.; Liu, T.H.; Chuang, M.H.; Hsu, W.H.; Huang, P.Y.; Lai, C.C.; Tsai, K.T.; Shiue, Y.L. Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data. J. Med. Virol. 2023, 95, e28869. [Google Scholar] [CrossRef]
  26. Liu, T.H.; Huang, P.Y.; Wu, J.Y.; Chuang, M.H.; Hsu, W.H.; Tsai, Y.W.; Chang, C.C.; Lai, C.C. Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data. J. Med. Virol. 2023, 95, e28801. [Google Scholar] [CrossRef] [PubMed]
  27. Liu, T.H.; Wu, J.Y.; Huang, P.Y.; Tsai, Y.W.; Lai, C.C. The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients. J. Infect. 2023, 86, 256–308. [Google Scholar] [CrossRef]
  28. CDC. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. Available online: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html (accessed on 6 April 2024).
  29. Foolchand, A.; Ghazi, T.; Chuturgoon, A.A. Malnutrition and Dietary Habits Alter the Immune System Which May Consequently Influence SARS-CoV-2 Virulence: A Review. Int. J. Mol. Sci. 2022, 23, 2654. [Google Scholar] [CrossRef]
  30. Mohammadi, A.H.; Behjati, M.; Karami, M.; Abari, A.H.; Sobhani-Nasab, A.; Rourani, H.A.; Hazrati, E.; Mirghazanfari, S.M.; Hadi, V.; Hadi, S.; et al. An overview on role of nutrition on COVID-19 immunity: Accumulative review from available studies. Clin. Nutr. Open Sci. 2023, 47, 6–43. [Google Scholar] [CrossRef]
  31. Iddir, M.; Brito, A.; Dingeo, G.; Fernandez Del Campo, S.S.; Samouda, H.; La Frano, M.R.; Bohn, T. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis. Nutrients 2020, 12, 1562. [Google Scholar] [CrossRef] [PubMed]
  32. Jin, D.; Wei, X.; He, Y.; Zhong, L.; Lu, H.; Lan, J.; Wei, Y.; Liu, Z.; Liu, H. The nutritional roles of zinc for immune system and COVID-19 patients. Front. Nutr. 2024, 11, 1385591. [Google Scholar] [CrossRef]
  33. Jamilian, A.; Ghalichi, F.; Hamedi Kalajahi, F.; Radkhah, N.; Jourabchi, N.; Musazadeh, V.; Amini-Salehi, E.; Zarezadeh, M.; Ostadrahimi, A. The role of vitamin D in outcomes of critical care in COVID-19 patients: Evidence from an umbrella meta-analysis of interventional and observational studies. Public Health Nutr. 2024, 27, e127. [Google Scholar] [CrossRef]
  34. SeyedAlinaghi, S.; Shahidi, R.; Mojdeganlou, H.; Akhtaran, F.K.; Maroufi, S.F.; Maroufi, S.P.; Mirzapour, P.; Karimi, A.; Khodaei, S.; Pour, M.M.; et al. The effect of macronutrient and micronutrient supplements on COVID-19: An umbrella review. J. Health Popul. Nutr. 2024, 43, 16. [Google Scholar] [CrossRef]
  35. Dellino, M.; Cascardi, E.; Vinciguerra, M.; Lamanna, B.; Malvasi, A.; Scacco, S.; Acquaviva, S.; Pinto, V.; Di Vagno, G.; Cormio, G.; et al. Nutrition as Personalized Medicine against SARS-CoV-2 Infections: Clinical and Oncological Options with a Specific Female Groups Overview. Int. J. Mol. Sci. 2022, 23, 9136. [Google Scholar] [CrossRef]
  36. Grund, S.; Bauer, J.M. Malnutrition and Sarcopenia in COVID-19 Survivors. Clin. Geriatr. Med. 2022, 38, 559–564. [Google Scholar] [CrossRef]
  37. Chiang, K.C.; Kalantar-Zadeh, K.; Gupta, A. Thymic Dysfunction and Atrophy in COVID-19 Disease Complicated by Inflammation, Malnutrition and Cachexia. Nutr. Health 2022, 28, 199–206. [Google Scholar] [CrossRef]
  38. Burgos, R.; García-Almeida, J.M.; Matía-Martín, P.; Palma, S.; Sanz-Paris, A.; Zugasti, A.; Alfaro, J.J.; Fullana, A.A.; Continente, A.C.; Chicetru, M.J.; et al. Malnutrition management of hospitalized patients with diabetes/hyperglycemia and COVID-19 infection. Rev. Endocr. Metab. Disord. 2022, 23, 205–213. [Google Scholar] [CrossRef]
  39. Fedele, D.; De Francesco, A.; Riso, S.; Collo, A. Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview. Nutrition 2021, 81, 111016. [Google Scholar] [CrossRef]
  40. Martín-Martínez, A.; Viñas, P.; Carrillo, I.; Martos, J.; Clavé, P.; Ortega, O. The Impact of Frailty, Oropharyngeal Dysphagia and Malnutrition on Mortality in Older Patients Hospitalized for COVID-19. Aging Dis. 2024, 15, 927–938. [Google Scholar] [CrossRef]
  41. Jima, L.M.; Atomsa, G.E.; Allard, J.P.; Nigatu, Y.D. The effect of malnutrition on adult Covid-19 patient’s ICU admission and mortality in Covid-19 isolation and treatment centers in Ethiopia: A prospective cohort study. PLoS ONE 2024, 19, e0298215. [Google Scholar] [CrossRef]
  42. Barazzoni, R.; Breda, J.; Cuerda, C.; Schneider, S.; Deutz, N.E.; Wickramasinghe, K. COVID-19: Lessons on malnutrition, nutritional care and public health from the ESPEN-WHO Europe call for papers. Clin. Nutr. 2022, 41, 2858–2868. [Google Scholar] [CrossRef]
  43. Wu, J.Y.; Liu, M.Y.; Liu, T.H.; Chuang, M.H.; Hsu, W.H.; Huang, P.Y.; Tsai, Y.W.; Lai, C.C. Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19. Int. J. Antimicrob. Agents 2023, 62, 106984. [Google Scholar] [CrossRef]
  44. Wu, J.Y.; Liu, M.Y.; Lee, M.C.; Hung, K.C.; Hsu, W.H.; Tsai, Y.W.; Liu, T.H.; Huang, P.Y.; Chuang, M.H.; Tseng, S.C.; et al. The clinical outcomes and effectiveness of antiviral agents among underweight patients with COVID-19. Expert. Rev. Anti Infect. Ther. 2024, 22, 343–352. [Google Scholar] [CrossRef]
  45. Boaz, M.; Kaufman-Shriqui, V. Systematic Review and Meta-Analysis: Malnutrition and In-Hospital Death in Adults Hospitalized with COVID-19. Nutrients 2023, 15, 1298. [Google Scholar] [CrossRef] [PubMed]
  46. Copeland, K.T.; Checkoway, H.; McMichael, A.J.; Holbrook, R.H. Bias due to misclassification in the estimation of relative risk. Am. J. Epidemiol. 1977, 105, 488–495. [Google Scholar] [CrossRef] [PubMed]
Life 14 00746 g001
Figure 1. Flowchart of the participant selection process. HCOs: healthcare organizations; y/o: years old; PCR: polymerase chain reaction.
Figure 1. Flowchart of the participant selection process. HCOs: healthcare organizations; y/o: years old; PCR: polymerase chain reaction.
Life 14 00746 g001
Life 14 00746 g002
Figure 2. Kaplan–Meier event-free curves for the primary outcome: a composite of all-cause hospitalization, all-cause mortality, or post-COVID-19 condition.
Figure 2. Kaplan–Meier event-free curves for the primary outcome: a composite of all-cause hospitalization, all-cause mortality, or post-COVID-19 condition.
Life 14 00746 g002
Table 1. Baseline characteristics of the study participants before and after the implementation of propensity-score matching.
Table 1. Baseline characteristics of the study participants before and after the implementation of propensity-score matching.
VariablesBefore MatchingAfter Matching
Malnutrition Group
(n = 15,004)		Control Group
(n = 2,662,662)		Std
Diff		Malnutrition Group
(n = 15,004)		Control Group
(n = 15,004)		Std
Diff
Age at index, years
 Mean ± SD66.0 ± 17.550.6 ± 19.20.8466.0 ± 17.566.8 ± 17.30.05
Gender, n (%)
 Female6960 (46.4)1,562,584 (58.7)0.256960 (46.4)7027 (46.8)<0.01
 Male7208 (48)992,649 (37.3)0.227208 (48)7125 (47.5)0.01
Race, n (%)
 White8687 (57.9)1,557,689 (58.5)0.018687 (57.9)8695 (58)<0.01
 American Indian or Alaska Native47 (0.3)7481 (0.3)0.0147 (0.3)41 (0.3)<0.01
 Native Hawaiian or Other Pacific Islander32 (0.2)12,099 (0.5)0.0432 (0.2)37 (0.2)<0.01
 Black or African American2373 (15.8)370,888 (13.9)0.052373 (15.8)2360 (15.7)<0.01
 Asian863 (5.8)111,754 (4.2)0.07863 (5.8)924 (6.2)0.02
 Other Race608 (4.1)116,846 (4.4)0.02608 (4.1)655 (4.4)0.02
Social determinants of health associated with adverse outcomes, n (%)
 Housing and economic circumstances584 (3.9)55,768 (2.1)0.11584 (3.9)533 (3.6)0.02
 Employment and unemployment224 (1.5)17,091 (0.6)0.08224 (1.5)183 (1.2)0.02
 Education and literacy83 (0.6)5473 (0.2)0.0683 (0.6)62 (0.4)0.02
 Occupational exposure to risk factors23 (0.2)5176 (0.2)0.0123 (0.2)24 (0.2)<0.01
Comorbidities, n (%)
 Alcohol-related disorders1339 (8.9)69,496 (2.6)0.271339 (8.9)1175 (7.8)0.04
 Nicotine dependence2660 (17.7)209,470 (7.9)0.302660 (17.7)2530 (16.9)0.02
 Hypertension7865 (52.4)799,286 (30)0.477865 (52.4)8061 (53.7)0.03
 Hyperlipidemia6174 (41.1)754,990 (28.4)0.276174 (41.1)6242 (41.6)<0.01
 Diabetes mellitus4407 (29.4)382,180 (14.4)0.374407 (29.4)4461 (29.7)<0.01
 Neoplasms5143 (34.3)546,655 (20.5)0.315143 (34.3)5146 (34.3)<0.01
 Chronic lower respiratory diseases3776 (25.2)408,114 (15.3)0.253776 (25.2)3800 (25.3)<0.01
 Diseases of liver2390 (15.9)166,690 (6.3)0.312390 (15.9)2307 (15.4)0.02
 Chronic kidney disease3358 (22.4)176,135 (6.6)0.463358 (22.4)3278 (21.8)0.01
 End-stage renal disease724 (4.8)30,343 (1.1)0.22724 (4.8)641 (4.3)0.03
 Cerebrovascular diseases3010 (20.1)151,654 (5.7)0.443010 (20.1)2917 (19.4)0.02
 Heart failure3015 (20.1)129,363 (4.9)0.473015 (20.1)2820 (18.8)0.03
 Atrial fibrillation and flutter2474 (16.5)129,184 (4.9)0.382474 (16.5)2417 (16.1)0.01
 Ischemic heart diseases4093 (27.3)253,795 (9.5)0.474093 (27.3)4024 (26.8)0.01
Std Diff: standardized difference. A standardized difference (Std diff) of <0.1 indicated an adequate balance between the two groups.
Table 2. Hazard ratios of the primary and secondary outcomes between the malnutrition group and control group.
Table 2. Hazard ratios of the primary and secondary outcomes between the malnutrition group and control group.
OutcomesPatients with OutcomeHazard Ratio
(95% CI)		p Value
Malnutrition GroupControl Group
Primary outcome
Post-COVID-19 condition or all-cause hospitalization, or death268313832.315 (2.170 to 2.471)<0.0001
Secondary outcomes
All-cause hospitalization228312572.151 (2.008 to 2.304)<0.0001
All-cause mortality5421384.459 (3.699 to 5.376)<0.0001
Post-COVID-19 condition109452.707 (1.913 to 3.832)<0.0001
CI: confidence interval.
Table 3. Subgroup analyses of the primary outcomes between the malnutrition and control groups.
Table 3. Subgroup analyses of the primary outcomes between the malnutrition and control groups.
Subgroup Analyses of Primary OutcomePatients with OutcomeHazard Ratio (95% CI)p Value
Malnutrition GroupControl Group
Gender
 Male13987272.306 (2.108 to 2.523)<0.0001
 Female12606872.203 (2.007 to 2.417)<0.0001
Age
 18–64 y/o11224592.848 (2.555 to 3.175)<0.0001
 ≥65 y/o164910531.897 (1.756 to 2.050)<0.0001
Race
 White204410392.337 (2.169 to 2.518)<0.0001
 American Indian or Alaska Native10104.777 (1.032 to 22.113)0.0271
 Native Hawaiian or Other Pacific Islander10101.596 (0.568 to 4.489)0.3698
 Black or African American4852622.163 (1.860 to 2.514)<0.0001
 Asian108492.863 (2.042 to 4.013)<0.0001
Vaccination status
 Unvaccinated205510882.261 (2.101 to 2.433)<0.0001
 Receiving ≥ 2 doses vaccination2021092.085 (1.652 to 2.632)<0.0001
Antiviral agent status
 Receiving antiviral agent50232.736 (1.669 to 4.486)<0.0001
 Not receiving antiviral agent292015402.246 (2.112 to 2.390)<0.0001
CI: confidence interval; y/o: years old.
Table 4. Subgroup analysis of the secondary outcomes between malnutrition and control groups.
Table 4. Subgroup analysis of the secondary outcomes between malnutrition and control groups.
SubgroupsAll-Cause
Hospitalization		All-Cause MortalityPost-COVID-19
Condition
HR (95% CI)p ValueHR (95% CI)p ValueHR (95% CI)p Value
Gender
 Male2.133 (1.940 to 2.344)<0.00015.022 (3.828 to 6.587)<0.00013.669 (2.164 to 6.219)<0.0001
 Female2.013 (1.825 to 2.220)<0.00015.143 (3.840 to 6.888)<0.00012.261 (1.339 to 3.818)0.0017
Age
 18–64 y/o2.634 (2.351 to 2.950)<0.00017.397 (4.861 to 11.256)<0.00013.949 (2.345 to 6.651)<0.0001
 ≥65 y/o1.718 (1.583 to 1.866)<0.00013.801 (3.100 to 4.660)<0.00011.873 (1.160 to 3.025)0.0091
Race
 White2.118 (1.956 to 2.293)<0.00015.024 (4.045 to 6.241)<0.00012.337 (1.646 to 3.32)<0.0001
 American Indian or Alaska Native4.255 (0.903,20.038)0.04601.010 (0.063 to 16.144)0.9945--
 Native Hawaiian or Other Pacific Islander1.246 (0.418 to 3.712)0.6920----
 Black or African American2.101 (1.796 to 2.458)<0.00012.852 (1.843 to 4.413)<0.00012.545 (1.078 to 6.624)0.0472
 Asian2.762 (1.938 to 3.936)<0.00017.821 (2.314 to 26.429)<0.00012.347 (0.430 to 12.828)0.3102
Vaccination status
 Unvaccinated2.128 (1.969 to 2.301)<0.00013.563 (2.913 to 4.358)<0.00013.164 (2.113 to 4.736)<0.0001
 Receiving ≥ 2 doses vaccination1.946 (1.514 to 2.500)<0.00013.401 (1.939 to 5.963)<0.00011.927 (0.712 to 5.210)0.1884
Antiviral agent status
 Receiving antiviral agent2.641 (1.588 to 4.393)<0.000111.964 (1.531 to 93.479)0.00251.134 (0.071 to 18.132)0.9290
 Not receiving antiviral agent2.068 (1.937 to 2.208)<0.00014.158 (3.492 to 4.952)<0.00013.234 (2.296 to 4.556)<0.0001
CI: confidence interval, HR: hazard ratio, y/o: years.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lee, C.-Y.; Liang, Y.-C.; Hsu, W.-H.; Tsai, Y.-W.; Liu, T.-H.; Huang, P.-Y.; Chuang, M.-H.; Hung, K.-C.; Lee, M.-C.; Yu, T.; et al. Malnutrition and the Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Multi-Institutional Population-Based Propensity Score-Matched Analysis. Life 2024, 14, 746. https://doi.org/10.3390/life14060746

AMA Style

Lee C-Y, Liang Y-C, Hsu W-H, Tsai Y-W, Liu T-H, Huang P-Y, Chuang M-H, Hung K-C, Lee M-C, Yu T, et al. Malnutrition and the Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Multi-Institutional Population-Based Propensity Score-Matched Analysis. Life. 2024; 14(6):746. https://doi.org/10.3390/life14060746

Chicago/Turabian Style

Lee, Cheng-Ya, Yung-Chun Liang, Wan-Hsuan Hsu, Ya-Wen Tsai, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Kuo-Chuan Hung, Mei-Chuan Lee, Tsung Yu, and et al. 2024. "Malnutrition and the Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Multi-Institutional Population-Based Propensity Score-Matched Analysis" Life 14, no. 6: 746. https://doi.org/10.3390/life14060746

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop